The philosophy for the management of chronic pelvic pain is based on a bio-psychosocial model. This is a holistic approach with patients’ active involvement. Single interventions rarely work in isolation and need to be considered within a broader personalised management strategy, including self-management. Pharmacological and non-pharmacological interventions should be considered with a clear understanding of the potential outcomes and endpoints. These may well include: psychology, physiotherapy, drugs and more invasive interventions.
Providing information that is personalised and responsive to the patient’s problems, conveying belief and concern, is a powerful way to allay anxiety . Additional written information or direction to reliable sources of information is useful; practitioners tend to rely on locally produced material or pharmaceutical products of variable quality while endorsing the need for independent materials for patients .
5.1. Conservative management
5.1.1. Pain education
It is always valuable to include education about the causes of pain, including eliciting from patients their anxieties about undiscovered pathology and addressing them. Information improves adherence to treatment and underpins self-management, as shown in bladder pain syndrome and in many other painful and non-painful disorders .
5.1.2. Physical therapy
The physiotherapist is part of the pain management team; (including doctors, psychologists and nurses). The therapeutic options for physiotherapists may not be the same in every country. Physiotherapists can either specifically treat the pathology of the pelvic floor muscles, or more generally treat myofascial pain if it is part of the pelvic pain syndrome. In most studies that have been done looking at the effect of physiotherapy in pelvic pain, the treatment of the pelvic floor is only part of the pain management. In a review about physiotherapy in women with pelvic pain, it was concluded that recommendations for physiotherapy should be given with caution . The review found six RCTs, of which three showed level 1b evidence with low-risk of bias. One of these three found that Mensendieck somatocognitive therapy showed a pain reduction after one year follow-up
of 64%. This approach consists of myofascial relaxation and tension, improving posture and movement in combination with cognitive behaviour therapy (CBT) .
Pelvic floor muscle pain
Treating pelvic floor over-activity and myofascial trigger points should be considered in the management of chronic pelvic pain. Treatment should be done by specialised physiotherapists who are trained not only in the musculo-skeletal aspects of pain, but also in the psychological mechanisms and the role of the CNS in chronic pain.
For patients with chronic pelvic pain and dysfunction of the pelvic floor muscles, it is very helpful to learn how to relax the muscles when the pain starts. By doing this, the circle of pain-spasm-pain can be interrupted. In the case of shortened muscles, relaxation alone is not enough. Stretching of the muscle is mandatory to regain length and function. Studies on physical therapy for pelvic floor pain syndrome have been sparse. A single blinded RCT with myofascial physical therapy and general body massage was carried out in patients with prostate or bladder pain. The global response rate (RR) to treatment with massage was significantly better in the prostate than in the bladder pain group (57% vs. 21%). In the prostate pain group, there was no difference between the two treatment arms. In the bladder pain group, myofascial treatment did significantly better than massage. Massage only improved complaints in the prostate pain group. The fact that gender distribution was different in each group is mentioned as a possible confounding factor .
Myofascial trigger point release
Treatment of myofascial trigger points can be done by manual therapy, dry needling and wet needling. The evidence for all the different treatments is weak, with most studies showing no significant difference between these techniques, though most studies were small and heterogeneous with regards to the patients and methods. There is no evidence that manual techniques are more effective than no treatment . Most studies of dry needling have compared with wet needling. Different SRs have come to the conclusion that, although there is an effect of needling on pain, it is neither supported nor refuted that this effect is better than placebo .
Physiotherapy in PBPS
Transvaginal manual therapy of the pelvic floor musculature (Thiele massage) in PBPS patients with high-tone dysfunction of the pelvic floor significantly improved several assessment scales . The role of specific levator ani trigger point injections in women with chronic pelvic pain has been studied . Each trigger point was identified by intravaginal palpation and injected with bupivacaine, lidocaine and triamcinolone. Seventy-two percent of women improved with the first trigger point injection, with 33% being completely pain-free. Efficacy and safety of pelvic floor myofascial physical therapy has been compared with global therapeutic massage in women with PBPS; global response assessment (GRA) rate was 59% and 26%, respectively. Pain, urgency and frequency ratings, and symptoms decreased in both groups during follow-up, and did not differ significantly between the groups. This suggests that myofascial physical therapy is beneficial in women with PBPS .
Primary Anal Pain Syndrome
An RCT demonstrated that biofeedback treatment was superior to electrogalvanic stimulation and massage of the Levator muscle for treating chronic primary anal pain syndrome . One hundred and fifty-seven patients who had at least weekly rectal pain were investigated, but only patients with tenderness on traction of the pelvic floor showed a significant treatment benefit. In patients with tenderness of the puborectalis muscle (Rome II: “Highly likely Levator Ani Syndrome”), 87% reported adequate relief after one month of biofeedback vs. 45% for electrogalvanic stimulation, and 22% for massage. These results were maintained at twelve months with adequate relief after nine sessions of biofeedback in 58% of the whole group (Rome II: “Highly likely” and “Possible Levator Ani Syndrome”), after galvanic stimulation in 27% and massage in 21% of patients. As previously described in dyssynergic defecation, the ability to expel a 50 mL water filled balloon and to relax pelvic floor muscles after biofeedback treatment were predictive of a favourable therapeutic outcome . The pathophysiology of the chronic primary anal pain syndrome is therefore similar to that of dyssynergic defecation, and this favours the role of the pelvic floor muscles in the pathophysiology of both conditions. Other treatment modalities have been less successful.
Treatment of sexual dysfunctions and chronic pelvic pain
Couples often benefit from early referral for relationship and sexual counselling during their treatment course . It needs to be remembered that sexual difficulties will arise as a result of pelvic pain syndromes as well as those disorders potentially being primary. Specific behavioural strategies for women who have urogenital complaints and female sexual dysfunction often include exploring alternatives to sexual intercourse (manual or oral pleasuring), different coital positions (female superior or side lying), and pacing, such as limiting the activity to less than that which causes pain. Planning for the time of intercourse is important, and scheduling a clinic visit after intercourse might be useful to identify specific sites and causes of post-coital flares. The corresponding evidence in men is lacking, but similar principles would apply. Other behavioural changes involve pre- and post-coital voiding, application of ice packs to the genital or suprapubic area [324,325], and increased use of vaginal dilators, fingers or sex toys. Lubricants can also be used and women with signs of vulvovaginal atrophy may benefit from oestrogen cream . Optimising the pelvic floor muscle is indicated when dysfunction is present and will relieve the pain [327-329].
Other physical therapy interventions
Electromagnetic therapy. A small, sham-controlled, double-blind study of four weeks showed a significant, sustained effect over a one-year period for CPPPS .
Extracorporeal shockwave therapy. A small sham-controlled double-blind study of four times weekly perineal extracorporeal shockwave therapy (n=30) in men with CPPPS showed significant improvement in pain, QoL, and voiding compared to the control group (n=30), over twelve weeks . Two other randomised shamcontrolled studies, have been published more recently, one comparing ten treatment sessions over two weeks (n=40 vs. n=40) , another with four times weekly treatments (n=20 vs. n=20) . Both concluded there was a significant effect in terms of total NIH-CPSI score and pain at twelve weeks. Unfortunately, no long term effects at 24 weeks could be shown in a published follow-up study of the second . A Cochrane review of non-pharmacological interventions for chronic pelvic pain reported a reduction in symptoms following treatment compared with control and concluded that extracorporeal shockwave therapy may improve symptoms without an increase in adverse events . In addition, a recent SR and meta-analysis concluded that extracorporeal shockwave therapy is effective for the improvement of pain and quality of life, but long-term efficacy was non-significant . Recent publications show a potential role for external shock wave lithotripsy applied to the bladder. In a RCT enrolling 54 patients, improvement in the VAS > 3 was 57.1% vs. 19.0% (ESWT vs. placebo; P =.011), at 12 weeks post treatment. However, primary endpoint did not reach significance .
Acupuncture. In a small three-arm RCT of CPPPS in men, electro-acupuncture was superior to sham treatment and advice and exercise alone . Another RCT comparing acupuncture (n=50) vs. sham-controlled (n=50), once weekly treatment for six weeks showed significant long lasting improvement at 24 weeks in terms of RR and overall symptom scores . Another RCT showed a significant effect for a follow-up of 32 weeks . Two SRs and meta-analyses were published in 2016 analysing seven RCTs on a total of 471 participants comparing acupuncture to sham control or oral medical treatment [343,344]. Both came to the conclusion that acupuncture was effective and safe, significantly reducing total NIH-CPSI scores compared to sham or medical treatment, and should be considered as a treatment option. This is in line with the conclusion of a recent Cochrane review  on non-pharmacological treatment options. However, the durability of this effect is not known.
Posterior tibial nerve stimulation. See section 5.3.2, Neuromodulation.
Transcutaneous electrical nerve stimulation. See section 5.3.2, Neuromodulation.
5.1.3. Psychological therapy
Psychological interventions may be directed at pain itself or at adjustment to pain in terms of function and mood and reduced health-care use, with or without pain reduction. Ideally, treatment follows general principles and practice in the field of chronic pain [345,346] but these have been neglected in pelvic pain. Two SRs and meta-analyses of the few heterogeneous trials of psychologically based treatment for pelvic pain [347,348]
found benefits for pain comparable to those from pharmacotherapy over a few months, but this was not sustained at follow-up. Exposure to pain-related fears in women with chronic pelvic pain proved superior to manual therapy in reducing those fears and overall pain disability, albeit assessed only by self-report . The importance of multi-disciplinary treatment is emphasised by several reviews [43,350,351] of intervention for diverse chronic pains, but standard multi-component psychologically-based programmes for pelvic pains are mostly in the pilot stages , with mixed findings so far . For less disabled and distressed patients treatment can be delivered remotely .
5.1.4. Dietary treatment
Scientific data are limited and dietary restriction alone does not produce significant symptomatic relief; however, consider the involvement of a dietician.
5.2. Pharmacological management
5.2.1. Drugs for chronic primary pelvic pain syndrome
In this section the evidence available for specific CPPPSs is presented. Where there is no evidence the reader is directed to the section on analgesics below (Section 5.2.2) where more generic use is discussed. There is a large discrepancy in the treatment effects reported in case series and controlled trials that results from a large placebo effect or publication bias. As a result of the multifactorial origin of for example PPPS, one reason for treatment failure in some large placebo-controlled RCTs, may be the heterogeneity of the patient population . One strategy for improving treatment effects may be stratification of patient phenotypes. A prospective series of phenotypically directed treatment for CPPPS has shown significant improvement of symptoms and QoL . Monotherapeutic strategies for the treatment of CPPPS may fail , therefore, most patients require multimodal treatment aimed at the main symptoms, and taking comorbidity into account. In the past ten years, results from RCTs have led to advances in standard and novel treatment options.
184.108.40.206. Mechanisms of action
Mechanisms of action are discussed as appropriate under the drugs headings below.
220.127.116.11. Comparisons of agents used in pelvic pain syndromes
Primary Prostate Pain Syndrome (PPPS)Anti-inflammatory drugs
For non-steroidal anti-inflammatory agents (NSAIDs), a trial with celecoxib reported that the pain sub-score, QoL sub-score, and total NIH-CPSI score were in favour of the treatment arm vs. placebo, but effects were limited to the duration of therapy . In a meta-analysis, two studies of NSAIDs [269,358] and one with prednisolone  were pooled. Anti-inflammatory drugs were 80% more likely to have a favourable response than placebo. In an updated network meta-analysis with more restrictive inclusion criteria regarding documented outcome measures but a wider spectrum of drugs (including glycosaminoglycans, phytotherapy and tanezumab), a significant effect on total NIH-CPSI scores and treatment response rates could be demonstrated. Overall, a moderate treatment effect has been shown for anti-inflammatory drugs, but larger studies are needed for confirmation, and long-term side-effects have to be taken into account.
Positive results from RCTs of α-blockers, i.e. terazosin [360,361], alfuzosin , doxazosin [363,364], tamsulosin [365,366], and silodosin  have led to widespread use of α-antagonists in the treatment of PPPS in recent years. Whereas one SR and meta-analysis has not reported a relevant effect of α-blockers due to study heterogeneity , another network meta-analysis of α-blockers  has shown significant improvement in total symptoms, pain, voiding, and QoL scores. In addition, they had a higher rate of favourable response compared to placebo [relative risk (RR): 1.4; 95% CI: 1.1-1.8, p=0.013]. However, treatment responsiveness, i.e., clinically perceptive or significant improvement, may be lower than expected from the change in mean symptom scores. Overall, α-blockers seem to have moderate but significant beneficial effects. This probably is not the case for long-standing PPPS patients . Future studies should show if longer duration of therapy or some sort of phenotypically directed (e.g., patients with PPPS and relevant voiding dysfunction) treatment strategies will improve treatment outcomes.
Empirical antibiotic therapy is widely used because some patients have improved with antimicrobial therapy. Patients responding to antibiotics should be maintained on medication for four to six weeks or even longer. Unfortunately, culture, leukocyte and antibody status of prostate-specific specimens do not predict antibiotic response in patients with PPS , and prostate biopsy culture findings do not differ from those of healthy controls . The only placebo-controlled RCTs of sufficient quality have been done for oral antibiotic treatment with ciprofloxacin (six weeks) , levofloxacin (six weeks) , and tetracycline hydrochloride (twelve weeks) . The studies have been analysed in meta-analyses [367,375]. Although direct meta-analysis has not shown significant differences in outcome measures, network meta-analysis has suggested significant effects in decreasing total symptom, pain, voiding, and QoL scores compared with placebo. Combination therapy of antibiotics with α-blockers has shown even better outcomes in network meta-analysis. Despite significant improvement in symptom scores, antibiotic therapy did not lead to statistically significant higher response rates . In addition, the sample sizes of the studies were relatively small and treatment effects only modest, mostly below clinical significance. It may be speculated that patients profiting from treatment had some unrecognised uropathogens. If antibiotics are used, other therapeutic options should be offered after one unsuccessful course of a quinolone or tetracycline antibiotic over six weeks. In addition, it is very important that unnecessary antibiotic use is avoided and local resistance patterns are considered. In this regard, the relevant recommendations of the EAU Guidelines on Urological Infections should be
Although a few small pilot studies with 5-α-reductase inhibitors supported the view that finasteride may improve voiding and pain, the first RCT published in a peer-reviewed journal did not support this, although the study lacked power . In another RCT, finasteride provided better amelioration of symptoms compared to saw palmetto over a one-year period, but lacked a placebo-control arm . A six-month placebo-controlled study showed a non-significant tendency towards better outcome in favour of finasteride, possibly because of a lack of statistical power . The NIH-CPSI scores decreased significantly in a subgroup of men enrolled in a prostate cancer risk reduction study treated with dutasteride compared to placebo . Patients (n=427, age 50 to 75, with elevated prostate-specific antigen [PSA]) were included if they had significant “prostatitis-like” symptoms at baseline. Based on the evidence, 5-α-reductase inhibitors cannot be recommended for use in PPPS in general, but symptom scores may be reduced in a restricted group of older men with an elevated PSA .
Phytotherapy applies scientific research to the practice of herbal medicine. An adequately powered placebo-controlled RCT of a pollen extract (Cernilton) showed clinically significant symptom improvement over a twelve week period in inflammatory PPPS patients (NIH Cat. IIIA) . The effect was mainly based on a significant effect on pain. Another pollen extract (DEPROX 500) has been shown to significantly improve total symptoms, pain and QoL compared to ibuprofen . In an RCT of patients treated with pollen extract suppositories (n=70) vs. oral ibupofen (n=71) over a period of ten days, the authors could find a clinically significant effect up to six months of follow-up including fewer adverse events in the pollen extract group . A SR and meta-analysis of pollen extract for the treatment of PPPS showed significant improvement in overall QoL . Quercetin, a polyphenolic bioflavonoid with documented antioxidant and anti-inflammatory properties, improved NIH-CPSI scores significantly in a small RCT . In contrast, treatment with saw palmetto, most commonly used for “benign prostatic hyperplasia”, did not improve symptoms over a one-year period . In a SR and meta-analysis, patients treated with phytotherapy were found to have significantly lower pain scores than those treated with placebo . In addition, overall RR in network meta-analysis was in favour of phytotherapy (RR: 1.6; 95% CI: 1.1-1.6).
Pregabalin is an anti-epileptic drug that has been approved for use in neuropathic pain. In an adequately powered placebo-controlled RCT, which was the only report included in a published Cochrane review , a six-week course of pregabalin (n=218) compared to placebo (n=106) did not result in a significant reduction of NIH-CPSI total score .
Pentosane polysulphate is a semi-synthetic drug manufactured from beech-wood hemicellulose. One study using oral high-dose (3 x 300 mg/day) demonstrated a significant improvement in clinical global assessment and QoL over placebo in men with PPPS, suggesting a possible common aetiology .
Muscle relaxants (diazepam, baclofen) are claimed to be helpful in sphincter dysfunction or pelvic floor/perineal muscle spasm, but there have been few prospective clinical trials to support these claims. In one RCT, a triple combination of a muscle relaxant (thiocolchicoside), an anti-inflammatory drug (ibuprofen) and an α-blocker (doxazosin) was effective in treatment-naïve patients, but not superior to an α-blocker alone .
Botulinum toxin type A (BTX-A) for the treatment of CPPPS is an off-label use, but a recent SR identified two RCTs and one non-randomised comparative study assessing intraprostatic BTX-A injections (100-200 units) for treatment of PPPS . All three papers used the NIH-CPSI to score pain. Although two of the studies reported a statistically significant reduction in pain, incomplete data and differences in dose and study methodology precluded calculation of a summary effect estimate for BTX-A-related improvement in pain. No definitive conclusions could be drawn from the review.
Zafirlukast, a leukotriene antagonist, and prednisone in two low-power placebo-controlled studies failed to show a benefit [359,388]. More recently, a placebo-controlled phase IIa study of tanezumab, a humanised monoclonal antibody that specifically inhibits the pain mediating neurotrophin, nerve growth factor, failed to demonstrate significant effect  and should only be used in clinical trials.
Primary Bladder Pain Syndrome (PBPS)Treatments of significant value for PBPSAnti-histamines
Mast cells may play a role in PBPS. Histamine is one of the substances released by mast cells. Histamine receptor antagonists have been used to block the H1  and H2  receptor subtypes, with variable results. A prospective placebo-controlled RCT of hydroxyzine or oral pentosane polysulphate did not show a significant effect .
Amitriptyline is a tricyclic antidepressant. Several reports have indicated improvement of PBPS symptoms after oral amitriptyline . Amitriptyline has been shown to be beneficial when compared with placebo plus behavioural modification . Drowsiness is a limiting factor with amitriptyline, nortriptyline is sometimes considered instead.
Pentosan polysulphate is a semi-synthetic drug manufactured from beech-wood hemicellulose. Subjective improvement of pain, urgency, frequency, but not nocturia, has been reported [397,398]. Pentosane polysulphate had a more favourable effect in PBPS type 3 C than in non-lesion disease . Response was not dose dependent but related more to treatment duration. At 32 weeks, about half the patients responded. Combination therapy showed a RR of 40% compared to 13% with placebo. For patients with an initial minor response to pentosane polysulphate, additional subcutaneous heparin was helpful [400,401].
Azathioprine treatment has resulted in disappearance of pain and urinary frequency . Initial evaluation of cyclosporin A (CyA)  and methotrexate  showed good analgesic effect but limited efficacy for urgency and frequency. Corticosteroids are not recommended in the management of patients with PBPS because of a lack of evidence.
Intravesical drugs are administered due to poor oral bio-availability establishing high drug concentrations within the bladder, with few systemic side-effects. Disadvantages include the need for intermittent catheterisation which can be painful in PBPS patients, cost and risk of infection .
- Local anaesthetics
There are sporadic reports of successful treatment of PBPS with intravesical lidocaine [406,407]. Alkalisation of lidocaine improves its pharmacokinetics . Combination of heparin, lidocaine and sodium bicarbonate gave immediate symptom relief in 94% of patients and sustained relief after two weeks in 80% . Intravesical instillation of alkalised lidocaine or placebo for five consecutive days resulted in significantly sustained symptom relief for up to one month .
- Hyaluronic acid and chondroitin sulphate
These are described to repair defects in the GAG layer. Despite the fact that intravesical GAG replenishment has been in use for about twenty years for PBPS/IC, most of the studies are uncontrolled and with a small number of patients. Based on the studies available there are differences by virtue of substance classes, whether they are natural GAG layer components, dosage formulations, or concentrations. A recent RCT seems to reinforce the case for GAG layer replenishment, however it lacks a placebo arm . A meta-analysis confirms usefulness of GAG layer replenishment. However most retrieved studies are non-randomised and with scarce numbers .
- Intravesical heparin
Primary bladder pain syndrome patients were treated with heparin for three months, and over half had control of symptoms, with continued improvement after one year of therapy . Kuo reported another trial of intravesical heparin for three months in women with frequency-urgency syndrome and a positive potassium test. Symptomatic improvement was reported in 80% of PBPS patients . Intravesical heparin plus peripheral neuromodulation in patients with refractory PBPS was studied and it was shown that voiding frequency, pain score and maximum cystometric capacity were significantly better after two and twelve
- Hyperbaric oxygen
This has a moderate effect on a small subgroup of PBPS patients. Disadvantages include high cost, limited availability of treatment sites, and time-consuming treatment .
Treatments of limited value for PBPS
There are limited data to suggest that cimetidine improves symptoms of PBPS in the short-term. Compared with placebo for three months, cimetidine significantly improved symptom scores, pain and nocturia, although the bladder mucosa showed no histological changes in either group .
Misoprostol is a prostaglandin that regulates various immunological cascades. After three months of treatment with misoprostol, fourteen out of 25 patients had significantly improved, with twelve showing a sustained response after a further six months . The incidence of adverse drug effects was 64%.
Oral treatment with the nitric oxide (NO) synthase substrate L-arginine decreases PBPS-related symptoms [418,419]. Nitric oxide is elevated in patients with PBPS . However, others have not demonstrated symptomatic relief or changes in NO production after treatment [421,422].
Oxybutynin is an anti-cholinergic drug used in overactive detrusor dysfunction. Intravesical oxybutynin combined with bladder training improves functional bladder capacity, volume at first sensation, and cystometric bladder capacity . However, an effect on pain has not been reported.
Duloxetine (a serotonin-noradrenaline re-uptake inhibitor antidepressant with a licence for the management of neuropathic pain) did not significantly improve symptoms of PBPS . Administration was safe, but tolerability was poor due to nausea. Based on these preliminary data, duloxetine cannot be recommended for treatment of PBPS.
Primary Scrotal Pain Syndrome (PSPS)
Treatment of primary scrotal pain syndrome is based on the principles of treating chronic pain syndromes, as described throughout these guidelines.
For scrotal pain post vasectomy, affected men may find that reversal of vasectomy can cure symptoms especially in those in whom patency is achieved . In a prospective RCT, pulsed radio-frequency to the ilioinguinal and genitofemoral nerves is associated with high rates of symptomatic improvement (80%) but follow up was limited to three months . The evidence for epididymectomy is poor but if considered, is less likely to provide benefit if the epididymis has a normal sonographic appearance .
Chronic gynaecological pain
It is difficult to compare the wide variation of drugs from an efficacy and safety perspective as they have such diverse uses/indications. In those gynaecological patients where chronic pelvic pain is unrelated to any of the well-defined conditions, it is often difficult to determine a therapeutic pathway other than a multi-disciplinary chronic abdomino-pelvic pain management plan. A Cochrane review suggests there may be some evidence (moderate) supporting the use of progestogens . Though efficacious, physicians need to be knowledgeable of progestogenic side effects (e.g., weight gain, bloatedness - the most common adverse effects) which can stop some patients from accepting such medication. Gonadotropin-releasing hormone (GnRH), such as goserelin, are also thought to help such pain. However, when compared with progestogens, their efficacy remains limited. The quality of evidence is generally low and drawn from single studies . Gonadotropin-releasing hormone on the other hand binds to specific receptors on pituitary gonadotrophs, leading to desensitisation and consequently to suppressed gonadotropin secretion. By contrast, GnRH antagonists compete with GnRH for receptors thus gonadotrophin secretion, which may be beneficial in certain clinical applications, such as reducing the size of fibroids, endometrial bleeding and endometriosis .
Pelvic Floor, Abdominal and Chronic Anal Pain
Botulinum toxin type A (pelvic floor)
Pelvic floor muscle over-activity plays a role in CPPPS. Botulinum toxin type A, as a muscle relaxant, can be used to reduce the resting pressure of the pelvic floor muscles and injection of the puborectalis and pubococcygeus muscles has been used to treat spasm of the levator ani A pilot study of 12 women with pelvic floor muscle overactivity as defined by a vaginal resting pressure > 40 cm H2O on vaginal manometry reported a reduction in resting pressure with improvement in dyspareunia and dysmenorrhoea, but no significant changes in non-menstrual pelvic pain scores . A recent SR including three RCTs comparing BTX-A with saline injections into the pelvic floor found no benefit in pain scores at six months follow-up despite a reduction in pelvic floor pressure .
Botulinum toxin type A has been injected into trigger points. It is more expensive than lidocaine and has not been proven to be more effective . Reviews do not support the injection of BTX-A into trigger points .
Botulinum toxin type A can also be injected at the sphincter level to improve urination or defecation. Relaxation of the urethral sphincter alleviates bladder problems and secondarily the spasm. In a cohort study of thirteen patients with CPPPS, BTX-A was injected into the external urethral sphincter. Subjectively, eleven patients reported a substantial change in pain symptoms, from a score of 7.2 to 1.6 on a VAS .
Intermittent chronic primary anal pain syndrome
Due to the short duration of the episodes, medical treatment and prevention is often not feasible. Inhaled β-2 adrenergic agonist salbutamol was effective in an RCT in patients with frequent symptoms and shortened pain duration . Other treatment options are topic diltiazem and BTX-A . However, there is still some controversy regarding the duration of pain of intermittent chronic and chronic primary anal pain syndrome. Randomised controlled trials often use different definitions, extending the pain duration (with a shift to chronic pain) in order to include more patients and to better evaluate the study-drug action.
Abdominal pain associated with Irritable Bowel Syndrome
Linaclotide, a minimally absorbed peptide guanylate cyclase-C agonist at a dose of 290 μg once daily significantly improved abdominal pain (48.9% vs. 34.5% placebo-treated) and bowel symptoms associated with IBS with constipation over 26 weeks of treatment . Diarrhoea was the most common adverse event in patients treated with linaclotide (4.5%). Although it is known to overlap with IBS pelvic pain, effect on the latter was not assessed in this study.
Delta-9-tetrahydrocannabinol (THC) shows only equivocal evidence of analgesic effects in chronic primary abdominal pain. In a recently published phase II trial, no difference was found between THC tablet and a placebo tablet in reducing pain outcome in patients with chronic abdominal pain .
If the use of simple analgesics fails to provide adequate benefit, then consider using neuropathic agents, and if there is no improvement, consider involving a specialist pain management centre with an interest in pelvic pain. Chronic pelvic pain is well defined and involves multiple mechanisms as described in previous sections.
The management requires a holistic approach with biological, psychological and social components. Few studies have specifically looked at medications used in CPPPS , therefore, a wider look at the literature has been undertaken and further specific research is required. The agents concerned are divided for ease of description. Combinations often provide a greater benefit than individual agents . They may also allow lower individual dosages and thus minimise side-effects. The aim of using these drugs is to allow patients to improve their QoL. This is best measured by assessing their function as well as pain severity. If the use of these agents does not allow this, then they should be withdrawn. Unfortunately, the failure of one agent does not exclude potential benefit of an alternative. If the benefit is limited by side-effects, then the lowest effective dose should be found (by dose titration). Sometimes, patients will prefer a higher level of pain and have fewer side-effects.
18.104.22.168. Mechanisms of action
Mechanisms of action are discussed as appropriate under the drug headings below.
22.214.171.124. Comparisons within and between groups in terms of efficacy and safety
Paracetamol is a well-tolerated analgesic in a class of its own. This is an antipyretic analgesic with a central mechanism of action . It is often available over the counter without prescription. A review questions its routine use as a first-line analgesic based on inadequate evidence of efficacy in many pain conditions including dysmenorrhoea . It will not be effective for all patients and individual responses should be reviewed when deciding on longer term use.
Non-steroidal anti-inflammatory agents
These agents are anti-inflammatory, antipyretic analgesics that act by inhibiting the enzyme cyclooxygenase (COX). They have a peripheral effect, hence their use in conditions involving peripheral or inflammatory mechanisms. They are commonly used for pelvic pain; many are available over the counter and are usually well-tolerated. There is insufficient evidence to suggest one NSAID over another for pelvic pain. Guidelines for use of NSAIDs and COX-2 selective agents have been developed. They have more side-effects than paracetamol, including indigestion, headaches and drowsiness.
The evidence for their benefit in chronic pelvic pain is weak or non-existent and is often limited by side-effects.
For pelvic pain in which inflammatory processes are considered important, such as dysmenorrhoea , NSAIDs are more effective than placebo and paracetamol, but with a higher incidence of side-effects. For pelvic pain in which central mechanisms may be incriminated, such as endometriosis  then the evidence is lacking for NSAIDs despite their common use.
At a practical level, if NSAIDs are considered for use, they should be tried (having regard for the cautions and contraindications) and the patient reviewed for improvement in function as well as analgesia. If this is not achieved, or side-effects are limiting, then they should be withdrawn.
These agents are not simple analgesics but used to modulate neuropathic or centrally mediated pain. There are several classes commonly used with recognised benefits in pain medicine. They are taken on a regular basis and all have side-effects that may limit their use and have the potential to be dependance-forming. In the UK, NICE has reviewed the pharmacological management of neuropathic pain . The evidence for treatment of CPPPS is lacking but is present for other painful conditions. For this chapter, most of the evidence is from non-pelvic pain sources. The general method for using these agents is by titrating the dose against benefit and side-effects. The aim is for patients to have an improvement in their QoL, which is often best assessed by alterations in their function. It is common to use these agents in combination but studies comparing different agents against each other, or in combination, are lacking. Some of these agents are also used for specific conditions. Early identification of neuropathic pain with a simple questionnaire could facilitate targeted therapy with neuromodulators .
The tricyclic antidepressants (TCAs) have multiple mechanisms of action and are frequently limited by their side-effects. Tricyclic antidepressants have a long history of use in pain medicine and have been subjected to a Cochrane review , suggesting that they are effective for neuropathic pain. Amitriptyline is the most commonly used at doses from 10-75 mg/day (sometimes rising to 150 mg/day). This is titrated against benefit or side-effects and should be taken at night . Nortriptyline and imipramine are used as alternatives.
Duloxetine is a SNRI antidepressant licensed for use in depression, SUI and neuropathic pain. There is evidence of benefit in diabetic neuropathy and fibromyalgia at a dose of 60 mg/day [446,447]. Side-effects are common and may result in its discontinuation.
Anticonvulsants are commonly used in the management of neuropathic pain. There are general studies and some looking more particularly at pelvic pain. Individual agents have been systematically reviewed. Their use is suggested in the NICE Neuropathic Pain Guidelines .
Carbamazepine has a long history of use in neuropathic pain. Evidence exists for its benefit . Trials trend to be of short duration, showing only moderate benefit. There are side-effects; some of which may be serious. It is no longer a first choice agent. Other anticonvulsant agents are available with fewer serious side-effects.
There is a growing awareness and evidence of the risk for dependence and misuse of gabapentinoids . A formal assessment of efficacy against benefit and side-effects (both pain and QoL) is required with the patient in order to determine the lowest effective dose and if longer-term treatment is to be used.
Gabapentin is commonly used for neuropathic pain and has been systematically reviewed [450,451]. This demonstrates good evidence for posterpatic neuralgia and diabeltic neuropathy but evidence for other neuropathies is limited. A double-blind RCT looking at CPPPS in women with no obvious pathology demonstrated no benefits but higher levels of side effect .
Pregabalin is a commonly used neuromodulator with good evidence of efficacy in some neuropathic conditions . The dose for benefit is in the range of 300-600 mg/day. Evidence for central neuropathic pains is inadequate. Some patients do gain moderate to significant benefit but most will gain no benefit and then the drug should be discontinued. Other agents can be used in the management of neuropathic pain but they are best administered by specialists in the management of pain whom are familiar with their use. They tend to be considered after the standard options have been exhausted. As with all good pain management, they are used as part of a comprehensive multi-dimensional management plan.
Over recent years opioids have been used extensively for managing chronic non-cancer pain. There is increasing evidence that their role is limited in this population but may be beneficial for a small number of patients at a low dose in a managed setting . There is clear evidence of harm and significant professional, public and political interest. Their use is beneficial for both acute pain and for cancer pain management particularly towards the end of life.
Often patients will stop taking oral opioids due to side effects or insufficient analgesic effect . There is clear evidence of harm including effects on the endocrine and immune systems as well as a growing understanding of opioid-induced hyperalgesia . There is limited guidance on the best method for tapering the dose of opioids with the aim of stopping or finding the lowest effective dose .
Opioids should only be used in conjunction with a management plan with consultation between clinicians experienced in their use. It is suggested that a pain management unit should be involved along with the patient and their primary care physician. Ensure there are arrangements for formal monitoring, follow-up and review. If opioids are used and the pain remains, then they are not working and should be stopped even if there is no alternative .
The risk of harm increases substantially at doses above 120 mg/day morphine equivalence  and guidance suggests regular (at least annual) review for patients with over 50 mg/day morphine equivalence and pain specialist involvement above 90 mg/day morphine equivalence .
There are well-established guidelines for the use of opioids in pain management as well as considering the potential risks [455,457]. Opioid reduction and optimisation should be undertaken where opioids are not providing clear measurable benefit. There is also information available online for patients . Opioids Aware is a web-based resource for patients and healthcare professionals, jointly produced by the Faculty of Pain Medicine of Royal College of Anaesthetists and Public Health England, to support prescribing of opioid medicines for pain. https://fpm.ac.uk/opioids-aware.
There has been increasing interest and changes in national regulations regarding the use of cannabinoids for medicinal use. Regarding pain the evidence base for the use of cannabinoids is weak [458-460] and further well conducted clinical trials are necessary. This is an area where further guidance and research is likely in the coming years.
5.3. Further management
5.3.1. Nerve blocks
Nerve blocks for pain management are usually carried out by specialists in pain medicine as part of a broader management plan . They may have a diagnostic or therapeutic role. Textbooks have been written on the subject and practitioners using them should be trained in appropriate patient selection, indications, risks and benefits. Many such interventions also require understanding and expertise in using imaging techniques to perform the blocks accurately. Diagnostic blocks can be difficult to interpret due to the complex mechanisms underlying the painful condition or syndrome. Sustained but limited benefit may lead to more permanent procedures (e.g., radiofrequency procedures). There is a weak evidence base for these interventions for chronic non-malignant pain .
The role of injections may be divided into two. First, an injection of local anaesthetic with or without steroids at the sight of nerve injury may produce a therapeutic action [463,464]. The second possible benefit is diagnostic. It has already been indicated that when the pudendal nerve is injured there are several sites where this may occur. Differential block of the pudendal nerve helps to provide information in relation to the site where the nerve may be trapped [260,465-472].
Infiltration at the ischial spine requires the use of a nerve stimulator/locator. Both motor (anal contraction) and sensory endpoints may be noted. The anatomical endpoint may be localised by fluoroscopy, CT guidance, or the use of US, the latter avoids any radiation, whereas CT guidance involves a significant amount of radiation. Currently, fluoroscopy is probably the imaging technique most frequently used because it is readily available to most anaesthetists that perform the block. Currently, infiltration of the pudendal nerve within Alcock’s canal is primarily undertaken with the use of CT. As well as injecting around the pudendal nerve, specific blocks of other nerves arising from the pelvis may be performed. Pulsed radio frequency stimulation has been suggested as a treatment . Pulsed radio frequency lesioning for pudendal neuralgia is being developed with a paper demonstrating potential benefit. Follow-up is short term and further research is required to better elucidate its place in management .
The role of neuromodulation in the management of pelvic pain should only be considered by specialists in pelvic pain management. These techniques are used as part of a broader management plan and require regular follow-up. The research base is developing and the techniques broadening (e.g., spinal cord stimulation, sacral root stimulation, dorsal root ganglion stimulation or peripheral nerve stimulation). These are expensive interventional techniques for patients refractory to other therapies. Neuromodulation is still finding its role in pelvic pain management. There has been growing evidence but more detailed, high quality research is required . Its role in overactive bladder (OAB) and faecal incontinence is more robust but is limited for pain. Two SRs have evaluated neuromodulation techniques for CPPS [476,477]. Both studies concluded that neuromodulation may be effective in reducing pain and improving QoL in patients with CPPS; however, studies were of a low quality and long-term results were needed.
Transcutaneous Electrical Nerve Stimulation
Transcutaneous electrical nerve stimulation (TENS) is a non-invasive technique used in many pain conditions. A SR identified twelve studies of TENS in chronic pelvic pain conditions including four RCTs . All RCTs demonstrated a significant reduction in pain following twelve weeks of treatment for pain conditions including dysmenorrhoea and CPPPS. Pain was also found to improve following TENS for provoked vestibular pain. There was conflicting data with regard to improvement of QoL following TENS; where validated questionnaires were used, no significant improvement was found, whereas in trialist-defined studies, an improvement was seen in TENS for dysmenorrhea and CPPPS. The beneficial effects of a course of TENS may be sustained; one study demonstrating a persistent benefit at 43 months in 73% of men with CPPPS and another demonstrating a prolonged significant improvement in women with provoked vestibular pain at ten months post-treatment. Where reported there were no adverse events recorded. Transcutaneous electrical nerve stimulation could offer an effective non-invasive treatment option for patients with CPPPS.
Percutaneous Tibial Nerve Stimulation
Percutaneous tibial nerve stimulation (PTNS) is a minimally invasive technique that can be use in an outpatient setting. Two SRs have shown that PTNS is effective in reducing pain in patients with CPPPS [476,477]. Three RCTs identified showed a significant improvement in pain scores and QoL as measured by validated questionnaires. Where recorded, adverse events were rare and minor including temporary slight pain at application site and haematoma.
Sacral Nerve Stimulation
Sacral nerve stimulation (SNS) is an invasive technique requiring sedation or general anaesthesia for implantation of a device following trial stimulation. A SR review identified ten studies of SNS in CPPPS, either retrospective case series or prospective cohort studies and no RCTs. Where reported, a mean of 69% of participants progressed to implantation of device following test stimulation (range 52-91%). All studies reported an improvement in pain, statistically significant in five studies. Quality of Life was measured in three studies and a significant improvement demonstrated in two of three studies. There was a large variation in adverse events reported ranging from 0-50%. Complications not requiring surgical intervention included pain, failure of device, wound infection and seroma. Re-operation rate ranged between 11-50% for complications including lead migration, systemic infection, intrathecal implantation, loss of efficacy and erosion. In clinical practice, a patient should be appropriately counselled regarding the need for a period of trial stimulation and whilst there may be an improvement in symptoms, this should be weighed against a notable complication rate.
A SR review in 2018 identified fourteen studies. In all, 403 patients had undergone percutaneous nerve evaluation and/or SNM stage 1 and 54.8%) had progressed to the permanent implantation stage, which is similar to that reported previously. The cause of pain was reported to be IC/BPS in 170 cases (42.2%). Visual Analogue Scale pain scores were available pre- and post-SNM in 210 patients and overall improvement in pain scores was significant. Sacral nerve stimulation is a promising treatment option for refractory chronic pelvic pain. This is mainly supported by level 2b studies. Randomised prospective studies are warranted to compare SNS vs. other modalities for chronic pelvic pain treatment. Further studies are needed to compare antegrade vs. retrograde approaches .
Other neuromodulation techniques
A variety of other techniques of neuromodulation for patients with CPPPS were identified by SRs [476,479]. These techniques include intravaginal electrical stimulation for women with CPPPS, pudendal nerve stimulation for CPPPS, spinal cord stimulation for pudendal neuralgia, transcutaneous interferential electrical stimulation for IBS, electrical acupuncture for dysmenorrhoea and electrical stimulation/biofeedback and electromagnetic stimulation for men with CPPPS. Whilst an improvement in pain has been reported in these studies, it is noted that they are largely of low quality and further work is needed in this area to enable robust clinical recommendations to be made. Neuromodulaution in combination with hormonal treatment in deep endometriosis may have some benefit .
Primary Bladder Pain Syndrome (PBPS)Bladder distension
Although bladder hydrodistension is a common treatment for PBPS, the scientific justification is scarce. It can be part of the diagnostic evaluation, but has limited therapeutic role.
Hydrodistension and Botulinum toxin type A
Botulinum toxin type A may have an anti-nociceptive effect on bladder afferent pathways, producing symptomatic and urodynamic improvements . Treatment with hydrodistension and hydrodistension plus intravesical BTX-A has been compared . There was symptomatic improvement in all patients. However, in the hydrodistension-only group, 70% returned to their previous symptoms after one month, while in the BTX-A-treated patients, VAS score and functional and cystometric bladder capacity improved at three months. Botulinum toxin type A trigonal-only injection seems effective and long-lasting as 87% of patients reported improvement after three months follow-up . Over 50% reported continued benefit nine months after the first treatment. When re-treatment was needed, similar results were obtained. Adverse effects of BTX-A administration for IC/PBPS were significantly less than for OAB syndrome, namely in increased post-void residual volumes and decreased voiding efficiency . Recent RCTs have reported benefits and long efficacy of BTX-A administration [485-488], but a summary estimate for overall change in pain following BTX-A injections was not possible in a recent SR . Conflicting data on results hinders issuance of a clear guideline for the use of Botox in PBPS phenetypes. Despite this, the American Urological Association (AUA) guidelines panel has upgraded BTX-A treatment from fifth to a fourth line treatment .
Results of treatment with intravesical plasma rich (PRP) injections are also being explored. A recent prospective trial, showed that patients with GRA (global response assessment) > 2, had success rates at one month and at three months after the 4th PRP injection, of 70.6% and 76.7%, respectively. The VAS pain score, frequency, and nocturia showed a significant decrease (all p < 0.05). However further studies are needed to validate findings .
Transurethral resection, coagulation and laser ablation
Endourological destruction of bladder tissue aims to eliminate urothelial Hunner lesions. Since the 1970s, resection and fulguration have been reported to achieve symptom relief, often for more than three years [491-493]. Prolonged amelioration of pain and urgency has been described for transurethral laser ablation as well .
Open Surgery for PBPS
Primary bladder pain syndrome is benign and does not shorten life, thus operative procedures rank last in the therapeutic algorithm. There is no evidence that it relieves pain. Surgery for PBPS is only appropriate as a last resort for patients with refractory disease. Major surgery should be preceded by thorough pre-operative evaluation, with an emphasis on determining the relevant disease location and subtype. If surgery is considered, the panel’s advice is to refer the patient to a specialist centre experienced in managing CPPPS with a multi-disciplinary team approach.
Four major techniques are common:
1.Urinary diversion without cystectomy is performed to minimise the duration and complexity of surgery, but complications related to the retained bladder commonly occur. Reports that un-resected PBPS bladders cease to induce symptoms after loss of contact with urine are scarce [103,495].
2.Supratrigonal cystectomy with bladder augmentation represents the most favoured continence-preserving surgical technique particularly in younger patients . Various intestinal segments have been used [497-499]. After orthotopic bladder augmentation, bladder emptying may be incomplete so intermittent self-catheterisation may be required. A study on female sexuality after cystectomy and orthotopic ileal neobladder showed pain relief in all patients and improvement in sexual function items in women who remained sexually active . Pregnancies with subsequent lower-segment Caesarean section have been reported after ileocystoplasty .
3.Subtrigonal or simple cystectomy refers to removal of the entire bladder at the level of the bladder neck. This approach has the benefit of removing the trigone as a possible disease site, but at the cost of requiring ureteric re-implantation. Trigonal disease is reported in 50% of patients and surgical failure has been blamed on the trigone being left in place , especially in patients with non-lesion type disease [503,504]. However, in a previous study all patients were rendered symptom-free by supratrigonal resection compared to 82% of those undergoing subtrigonal cystectomy. Voiding dysfunction is most likely to occur following trigonal resection and patients considering augmentation and especially substitution procedures must be capable of accepting, performing and tolerating self-catheterisation .
4.Cystectomy with formation of an ileal conduit is considered for patients with PBPS who develop recurrent pain in the augmented bladder, continent pouch after enterocystoplasty or continent urinary diversion. Re-tubularisation of a previously used bowel segment to form a urinary conduit has been recommended .
Primary Prostate Pain Syndrome
There is no evidence for surgical management, including transurethral incision of the bladder neck, radical transurethral resection of the prostate or, in particular, radical prostatectomy in the management of chronic pain in patients with PPPS. A large Chinese RCT of circumcision combined with a triple oral therapy (ciprofloxacin, ibuprofen, tamsulosin) vs. oral therapy alone has been published for patients with PPPS (total n=774) . It is hypothesised that there may be some immunological interaction via pathogenic antigen presenting cells in the foreskin with CD4+ T cells causing auto-immunity to the prostate gland. They reported an improvement in total NIH-CPSI score and subdomain scores at twelve weeks. However, despite a large cohort, the study results are questionable because of the weak theoretical background, and a potential large placebo effect lacking a sham control. In addition, no long-term effectiveness has been reported. Before having an impact on recommendations, the results of this study have to be independently confirmed and the treatment effect must persist.
Primary Testicular Pain Syndrome
Microsurgical denervation of the spermatic cord can be offered to patients with testicular pain. In a long-term follow-up study, patients who had a positive result on blocking the spermatic cord were found to have a good result following denervation [508,509].
Chronic Primary Anal and Abdominal Pain Syndrome
Chronic primary anal pain syndrome after stapled procedures, such as hemorrhoidopexy or stapled transanal rectal resection may respond to excision of the scarred staple line as shown in 21 consecutive patients with an overall improvement of pain in 85.7% of patients undergoing scar excision surgery . An early scar excision before three to six months after pain onset was associated with better pain relief. Adhesiolysis is still in discussion in the pain management after laparotomy/laparoscopy for different surgical indications in the pelvis and entire abdomen. An RCT has shown, that adhesiolysis is associated with an increased risk of operative complications, and additional operations and increased health care costs as compared to laparoscopy
Primary Urethral Pain Syndrome
There is no specific treatment that can be advised. Management should be multi-disciplinary and multi-modal . Laser therapy of the trigonal region may be a specific treatment. One trial comparing two forms of laser reported good results, but did not compare with sham treatment . The majority of publications on treatment of primary urethral pain syndrome have come from psychologists [167,514].
Presumed intra-abdominal adhesions
In gynaeocological patients with CPPPS and presumed adhesions, there is no consensus as to whether adhesiolysis should be performed to improve pain .
Extensive surgery for endometriosis is challenging and is still considered to be controversial, as there is at least one RCT showing no benefit in pain relief after the removal of early extensive endometriosis vs. sham surgery [272,515]. Increasingly treatment algorithms are being developed using a multi-disciplinary approach, although none have thus far been proven clinically . In patients with adenomyosis, the only curative surgery is hysterectomy but patients can benefit from hormonal therapy and analgesics (see Section 5.2.2).
Pudendal neuralgia and surgery
Decompression of an entrapped or injured nerve is a routine approach and probably should apply to the pudendal nerve as it applies to all other nerves. There are several approaches and the approach of choice probably depends upon the nature of the pathology. The most traditional approach is transgluteal; however, a transperineal approach may be an alternative, particularly if the nerve damage is thought to be related to previous pelvic surgery [198,260,517-520]. Currently, there has been only one prospective RCT (transgluteal approach) . This study suggests that, if the patient has had the pain for less than six years, 66% of patients will see some improvement with surgery (vs. 40% if the pain has been present for more than six years). Surgery is not the answer for all patients. On talking to patients that have undergone surgery, providing the diagnosis was clear-cut, most patients were grateful to have undergone surgery but many still have symptoms that need management.
Chronic Pelvic Pain and Prolapse/Incontinence Mesh
Removing an existing mesh is a complex procedure . Each patient is approached on an individual basis depending on the type of mesh and extent of complications . The complexity of surgery often involves removal of dense scar tissue, reformation of inflamed vaginal skin and surgical reconstruction of the urethra and bladder . Such surgery requires specialist skills, best provided within a multi-disciplinary tertiary setting. Possible complications as a result of this surgical removal include bleeding, infection, damage to surrounding organs as well as LUTS, persistent chronic pain and recurrent SUI, which occurs after mesh removal .
Removal of mesh, whilst complex, does have beneficial outcomes generally, which are also durable particularly for chronic pain . However, the long-term consequences after the mesh is removed still can include, not only chronic persistent pain but also autoimmune responses and complex neuropathies affecting the pelvis and lower limbs [526,527]. Some of these can be treated effectively using a multi-disciplinary pain medicine approach . In other cases, the residual symptoms may require the input of an immunologist, rheumatologist or other symptom-defined specialist.
The alternative to continence and prolapse mesh surgery is dependent on the clinical findings at the time. They include behavioural change, physiotherapy (for SUI and Grade I-II uterovaginal prolapse) or traditional surgical techniques. Studies have shown that over 70% who committed to physiotherapy for SUI often did not need any further intervention . Many clinicians are reverting to conservative measures first, before re-considering surgery. Clinicians are also now retraining in traditional continence surgical techniques, which existed in the pre-mesh era, such as the Burch colposuspension and autologous fascial sling; as well as traditional utero-vaginal prolapse techniques such as vaginal hysterectomy, sacrospinous fixation and fascial repair of vaginal wall prolapse.
5.4. Summary of evidence and recommendations: management
5.4.1. Management of primary prostate pain syndrome
Summary of evidence
Phenotypically directed treatment may improve treatment success.
α-blockers have moderate treatment effect regarding total pain, voiding, and QoL scores in PPPS.
Antimicrobial therapy has a moderate effect on total pain, voiding, and QoL scores in PPPS.
Non-steriodal anti-inflammatory drugs have moderate overall treatment effects on PPPS.
Phytotherapy has some beneficial effect on pain and overall favourable treatment response in PPPS.
Pentosane polysulphate improves global assessment and QoL score in PPPS.
There are insufficient data on the effectiveness of muscle relaxants in PPPS.
Pregabalin is not effective for the treatment of PPPS.
Botulinum toxin type A injection into the pelvic floor (or prostate) may have a modest effect in PPPS.
Acupuncture is superior to sham acupuncture in improving symptoms and QoL.
Posterior tibial nerve stimulation is probably effective for the treatment of PPPS.
Extracorporeal shock wave therapy is probably effective over the short term.
There are insufficient data supporting the use of other surgical treatments, such as transurethral incision of the bladder neck, transurethral resection of the prostate, or radical prostatectomy in patients with PPPS.
Cognitive behavioural therapy designed for PPPS may improve pain and QoL.
Offer multimodal and phenotypically directed treatment options for Primary Prostate Pain Syndrome (PPPS).
Use antimicrobial therapy (quinolones or tetracyclines) over a minimum of six weeks in treatment-naïve patients with a duration of PPPS less than one year.
Use α-blockers for patients with a duration of PPPS less than one year.
Offer high-dose oral pentosane polysulphate in PPPS.
Offer acupuncture in PPPS.
Offer non-steroidal anti-inflammatory drugs (NSAIDs) in PPPS, but long-term side-effects have to be considered.
5.4.2. Management of primary bladder pain syndrome
Summary of evidence
There is insufficient data for the long-term use of corticosteroids.
Limited data exist on effectiveness of cimetidine in PBPS.
Amitriptyline is effective for pain and related symptoms of PBPS.
Oral pentosane polysulphate is effective for pain and related symptoms of PBPS.
Oral pentosane polysulphate plus subcutaneous heparin is effective for pain and related symptoms of PBPS, especially in initially low responders to pentosane polysulphate alone.
Intravesical lidocaine plus sodium bicarbonate is effective in the short term.
Intravesical pentosane polysulphate is effective, based on limited data, and may enhance oral treatment.
There are limited data on the effectiveness of intravesical heparin.
Intravesical chondroitin sulphate may be effective.
There is insufficient data for the use of bladder distension as a therapeutic intervention.
Hydrodistension plus BTX-A is superior to hydrodistension alone.
Intravesical BCG is not effective in PBPS.
Transurethral resection (coagulation and laser) may be effective in PBPS type 3 C.
Sacral neuromodulation may be effective in PBPS.
Pudendal nerve stimulation is superior to sacral neuromodulation for treatment of PBPS.
Avoidance of certain foods and drink may reduce symptoms.
Outcome of cystectomy for PBPS is variable.
Offer subtype and phenotype-oriented therapy for the treatment of Primary Bladder Pain Syndrome (PBPS).
Always consider offering multimodal behavioural, physical and psychological techniques alongside oral or invasive treatments of PBPS.
Offer dietary advice.
Administer amitriptyline for treatment of PBPS.
Offer oral pentosane polysulphate for the treatment of PBPS.
Offer oral pentosane polysulphate plus subcutaneous heparin in low responders to pentosane polysulphate alone.
Do not recommend oral corticosteroids for long-term treatment.
Offer intravesical hyaluronic acid or chondroitin sulphate before more invasive measures.
Offer intravesical lidocaine plus sodium bicarbonate prior to more invasive methods.
Offer intravesical heparin before more invasive measures alone or in combination treatment.
Do not use bladder distension alone as a treatment of PBPS.
Consider submucosal bladder wall and trigonal injection of botulinum toxin type A plus hydrodistension if intravesical instillation therapies have failed.
Offer neuromodulation before more invasive interventions.
Only undertake ablative and/or reconstructive surgery as the last resort and only by experienced and PBPS-knowledgeable surgeons, following a multi-disciplinary assessment including pain management.
Offer transurethral resection (or coagulation or laser) of bladder lesions, but in PBPS type 3 C only.
5.4.3. Management of scrotal pain syndrome
Summary of evidence
Microsurgical denervation of the spermatic cord is an effective therapy for primary scrotal pain syndrome.
Vasovasostomy is effective in post-vasectomy pain.
Inform about the risk of post-vasectomy pain when counselling patients planned for vasectomy.
Do open instead of laparoscopic inguinal hernia repair, to reduce the risk of scrotal pain.
In patients with testicular pain improving after spermatic block, offer microsurgical denervation of the spermatic cord.
5.4.4. Management of primary urethral pain syndrome
Summary of evidence
There is no specific treatment for primary urethral pain syndrome.
5.4.5. Management of gynaecological aspects of chronic pelvic pain
Summary of evidence
Therapeutic options, including pharmacotherapy and surgery, can treat endometriosis effectively.
Psychological treatment (CBT or supportive psychotherapy) can improve pain and sexual and emotional function in vaginal and vulvar pain syndrome.
Most gynaecological pain conditions (including dysmenorrhea, post-mesh insertion and gynaecological malignancy) can be treated effectively using pharmacotherapy.
All other gynaecological conditions (including obstetric injury, pelvic organ prolapse) can be treated effectively using surgery.
Involve a gynaecologist to provide therapeutic options such as hormonal therapy or surgery in well-defined disease states.
Provide a multi-disciplinary approach to pain management in persistent disease states.
All patients who have developed complications after mesh insertion should be referred to a multi-disciplinary service (incorporating pain medicine and surgery).
5.4.6. Management of primary anorectal pain syndrome
Summary of evidence
Biofeedback is the preferred treatment for Chronic Primary Anal Pain Syndrome.
Electro-galvanic stimulation is less effective than biofeedback.
Available evidence fails to confirm effectiveness of BTX-A in management of Chronic Primary Anal Pain Syndrome.
Percutaneous tibial nerve stimulation is effective in anal pain.
Sacral neuromodulation is effective in anal pain.
Inhaled salbutamol is effective in intermittent Chronic Primary Anal Pain Syndrome.
Undertake biofeedback treatment in patients with chronic anal pain.
Offer percutaneous tibial nerve stimulation in Chronic Primary Anal Pain Syndrome.
Offer sacral neuromodulation in Chronic Primary Anal Pain Syndrome.
Offer inhaled salbutamol in intermittent Chronic Primary Anal Pain Syndrome.
5.4.7. Management of pudendal neuralgia
Summary of evidence
There are multiple treatment options with varying levels of evidence.
Neuropathic pain guidelines are well-established. Use standard approaches to management of neuropathic pain.
5.4.8. Management of sexological aspects in chronic pelvic pain
Summary of evidence
Pelvic floor muscle physical therapy may offer relief of pain and reduction in sexual complaints.
Offer behavioural strategies to the patient and his/her partner to reduce sexual dysfunctions.
Offer pelvic floor muscle therapy as part of the treatment plan to improve quality of life and sexual function.
5.4.9. Management of psychological aspects in chronic pelvic pain
For chronic pelvic pain with significant psychological distress, refer patient for chronic pelvic pain-focused psychological treatment.
5.4.10. Management of pelvic floor dysfunction
Summary of evidence
Myofascial treatment is effective.
Biofeedback improves the outcome of myofascial therapy.
Apply myofascial treatment as first-line treatment.
Offer biofeedback as therapy adjuvant to muscle exercises, in patients with anal pain due to an overactive pelvic floor.
5.4.11. Management of chronic/non-acute urogenital pain by opioids
Opioids and other drugs of addiction/dependency should only be prescribed following multi-disciplinary assessment and only after other reasonable treatments have been tried and failed.
The decision to instigate long-term opioid therapy should be made by an appropriately trained specialist in consultation with the patient and their family doctor.
Where there is a history or suspicion of drug abuse, involve a psychiatrist or psychologist with an interest in pain management and drug addiction.